Fulgent Q2 core revenue $70.2M (+5% YoY); GAAP loss $0.29/share improves EPS guidance

Fulgent Genetics, Inc.

Total revenue $71.0M; core revenue $70.2M (+5% YoY).
GAAP net loss $8.7M ($0.29 per share); Non-GAAP income $4.7M ($0.15 per share).
Adjusted EBITDA loss $727K; cash from ops $4.3M; cash and investments $837.9M.
Reiterates FY2024 core revenue guidance $280M; improves EPS guidance.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.